2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P11297
    AC-SDKP-NH2 194484-75-8 98%
    AC-SDKP-NH2 is a substrate peptide of Angiotensin converting enzyme (ACE). AC-SDKP-NH2 has anti-inflammatory and anti-fibrotic activities. AC-SDKP-NH2 directly acts on tissues and prevents or reverses them from excessive fibrosis, but fails to reduce blood pressure and left ventricular hypertrophy (LVH). AC-SDKP-NH2 attenuates inflammation and cell differentiation, proliferation and migration, therefore reducing fibrosis in the heart, vessels and kidneys in mice model. AC-SDKP-NH2 can be used for cardiovascular diseases such as hypertension research.
    AC-SDKP-NH2
  • HY-P11300
    YKYY 305370-00-7 98%
    YKYY, a antihypertensive peptide, is an Angiotensin I-converting enzyme (ACE) inhibitor with an IC50 of 64.2 μM. YKYY can be isolated for the peptic digest of wakame Undaria pinnatifida. YKYY can be used for hypertension research.
    YKYY
  • HY-P11313
    Catestatin (rat) 98%
    Catestatin (rat) (Rat chromogranin A367–387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 μM), and blocks desensitization of norepinephrine release (IC50 = 0.62 μM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3β at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na+ uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms.
    Catestatin (rat)
  • HY-P11314
    ABri 241145-90-4
    ABri, 34 amino acids long, is an Amyloid subunit with certain degree of N- and C-terminal heterogeneity and no sequence identity to any known amyloid protein. ABri is devoid of glycine, methionine, proline, aspartic acid, tryptophane, tyrosine and glutamine, featuring pyroglutamate at its N-terminus. ABri can be used for cerebral hemorrhages, ischemic infarction and Alzheimer disease research.
    ABri
  • HY-P11447
    COLIV-peptide 2121574-86-3
    COLIV-peptide is a type of specific binding peptide that can recognize and bind to Collagen Ⅳ, a key non-cellular component in atherosclerotic plaques. COLIV-peptide can be used for the study of atherosclerotic.
    COLIV-peptide
  • HY-P11495
    myr-RGT 1126379-15-4
    myr-RGT is a nutmeg acylated RGT peptide. myr-RGT can be used to inhibit extracellular signaling of integrin β3. myr-RGT can be used in the research of atherosclerosis and other related conditions.
    myr-RGT
  • HY-P1166A
    UFP-803 TFA 98%
    UFP-803 TFA is a potent urotensin-II receptor (UT) ligand. UFP-803 TFA has lower residual agonist activity, so it may be an important tool for the investigations on the role played by the UT system in physiology and pathology.
    UFP-803 TFA
  • HY-P1167A
    [Orn5]-URP TFA 98%
    [Orn5]-URP TFA is a potent and selective pure antagonist of Urotensin-II receptor (UT), with an pEC50 of 7.24. [Orn5]-URP TFA displays no agonist activity.
    [Orn5]-URP TFA
  • HY-P1184A
    HNGF6A TFA 98%
    HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo.
    HNGF6A TFA
  • HY-P1214A
    γ1-MSH TFA 98%
    γ1-MSH TFA is a melanocortin MC3 receptor agonist, with a Ki of 34 nM for the rat MC3 receptor. γ1-MSH TFA displays ~40-fold selectivity over MC4 (Ki=1318 nM).
    γ1-MSH TFA
  • HY-P1262A
    Parstatin(human) TFA 98%
    Parstatin(human) TFA, a cell-penetrating PAR-1 thrombin receptor agonist peptide, is a potent inhibitor of angiogenesis.
    Parstatin(human) TFA
  • HY-P1306A
    Obestatin(rat) TFA 1312186-27-8 98%
    Obestatin(rat) TFA, encoded by the Ghrelin gene, is a cpeptide, comprised of 23 amino acids. Obestatin(rat) TFA suppresses food intake, inhibits jejunal contraction, and decreases body-weight gain. Obestatin is an endogenous ligand of G-protein coupled receptor 39 (GPR39). Obestatin(rat) TFA has anti-inflammatory, anti-myocardial infarction and antioxidant activities.
    Obestatin(rat) TFA
  • HY-P1419A
    AP 811 acetate 98%
    AP 811 acetate is a selective atrial natriuretic peptide clearance receptor (ANP-CR, NPR3) antagonist with a Ki of 0.48 nM. AP 811 acetate displays >20000-fold selectivity for NPR3 over NPR1. AP 811 acetate abolishes ANP-induced pump stimulation.
    AP 811 acetate
  • HY-P1428A
    RFRP-1(human) TFA 98%
    RFRP-1(human) TFA is a potent endogenous NPFF receptor agonist (EC50 values are 0.0011 and 29 nM for NPFF2 and NPFF1, respectively). Attenuates contractile function of isolated rat and rabbit cardiac myocytes. Reduces heart rate, stroke volume, ejection fraction and cardiac output, and increases plasma prolactin levels in rats.
    RFRP-1(human) TFA
  • HY-P1435A
    NoxA1ds TFA 98%
    NoxA1ds TFA is a potent and highly selective NADPH oxidase 1 (NOX1) inhibitor (IC50=20 nM). NoxA1ds TFA inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. NoxA1ds TFA attenuates VEGF-induced human pulmonary artery endothelial cell migration under hypoxic conditions in vitro. NoxA1ds TFA can be used in the study of hypertension, atherosclerosis and tumors.
    NoxA1ds TFA
  • HY-P1471A
    Adrenomedullin (AM) (22-52), human TFA 98%
    Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat.
    Adrenomedullin (AM) (22-52), human TFA
  • HY-P1486A
    Angiotensinogen (1-14), human TFA 98%
    Angiotensinogen (1-14), human TFA is a fragment of the renin substrate angiotensinogen. Angiotensinogen is naturally occurring substrate for renin and a precursor for all angiotensin peptides.
    Angiotensinogen (1-14), human TFA
  • HY-P1548B
    β-CGRP, human acetate 98%
    β-CGRP, human acetate (Human β-CGRP acetate) is one of calcitonin peptides, acts via the complex of calcitonin-receptor-like receptor (CRLR) and receptor-activity-modifying protein (RAMP), with IC50s of 1 nM and 300 nM for CRLR/RAMP1 and CRLR/RAMP2 in cells.
    β-CGRP, human acetate
  • HY-P1573A
    Brain Natriuretic Peptide-45, rat TFA 98%
    Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is a circulating form of rat brain natriuretic peptide isolated from rat heart with potent hypotensive and natriuretic potency.
    Brain Natriuretic Peptide-45, rat TFA
  • HY-P1636A
    Hirudin (54-65) TFA 98%
    Hirudin (54-65) TFA is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.
    Hirudin (54-65) TFA
Cat. No. Product Name / Synonyms Application Reactivity